Purdue Pharma taps TetraGenetics for ion channel-focused pain treatments in $273M discovery pact
Purdue Pharma’s newly formed clinical research subsidiary, Imbrium Therapeutics, has tapped TetraGenetics and its antibody discovery platform to help it develop new, non-opioid-based biologics for treating chronic pain. Read more >>